Teva Pharmaceutical Industries (TEVA) Cut to “Neutral” at BTIG Research

Teva Pharmaceutical Industries (NYSE:TEVA) was downgraded by BTIG Research from a “buy” rating to a “neutral” rating in a report released on Thursday, Marketbeat.com reports. They presently have a $24.00 target price on the stock. BTIG Research’s target price would suggest a potential upside of 11.73% from the stock’s previous close. The analysts noted that the move was a valuation call.

Other research analysts have also issued reports about the stock. Goldman Sachs Group boosted their price target on shares of Teva Pharmaceutical Industries from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, January 11th. Credit Suisse Group restated an “underperform” rating and set a $8.00 price target (down from $14.00) on shares of Teva Pharmaceutical Industries in a research report on Monday, November 6th. Morgan Stanley upgraded shares of Teva Pharmaceutical Industries from an “underweight” rating to an “equal weight” rating and set a $18.00 price target for the company in a research report on Friday, December 15th. Royal Bank of Canada set a $11.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “sell” rating in a research report on Wednesday, November 29th. Finally, Cantor Fitzgerald set a $10.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Thursday, December 14th. Eight research analysts have rated the stock with a sell rating, sixteen have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Teva Pharmaceutical Industries has an average rating of “Hold” and a consensus price target of $21.32.

Shares of Teva Pharmaceutical Industries (NYSE TEVA) traded up $0.07 during mid-day trading on Thursday, reaching $21.48. 17,033,000 shares of the company’s stock were exchanged, compared to its average volume of 23,465,754. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. Teva Pharmaceutical Industries has a 1-year low of $10.85 and a 1-year high of $37.94. The company has a market cap of $20,710.00, a PE ratio of -3.66, a price-to-earnings-growth ratio of 1.53 and a beta of 0.54.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Thursday, November 2nd. The company reported $0.95 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.03 by ($0.08). Teva Pharmaceutical Industries had a negative net margin of 24.35% and a positive return on equity of 15.70%. analysts forecast that Teva Pharmaceutical Industries will post 3.72 EPS for the current fiscal year.

A number of large investors have recently made changes to their positions in the stock. Exane Derivatives bought a new stake in Teva Pharmaceutical Industries in the third quarter worth $571,000. Korea Investment CORP lifted its stake in Teva Pharmaceutical Industries by 14.3% in the third quarter. Korea Investment CORP now owns 244,774 shares of the company’s stock worth $4,308,000 after purchasing an additional 30,674 shares during the last quarter. Private Capital Management Inc. lifted its stake in Teva Pharmaceutical Industries by 51.3% in the third quarter. Private Capital Management Inc. now owns 26,100 shares of the company’s stock worth $459,000 after purchasing an additional 8,850 shares during the last quarter. Financial Counselors Inc. lifted its stake in Teva Pharmaceutical Industries by 28.8% in the third quarter. Financial Counselors Inc. now owns 181,130 shares of the company’s stock worth $3,188,000 after purchasing an additional 40,531 shares during the last quarter. Finally, Lockheed Martin Investment Management Co. bought a new stake in Teva Pharmaceutical Industries in the third quarter worth $317,000. Institutional investors own 51.96% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Teva Pharmaceutical Industries (TEVA) Cut to “Neutral” at BTIG Research” was reported by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/01/18/btig-research-downgrades-teva-pharmaceutical-industries-teva-to-neutral.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply